<DOC>
	<DOC>NCT01025791</DOC>
	<brief_summary>A three panel study, to determine if MK8266 given as a single dose is sufficiently safe and well tolerated. Panel A and B will consist of healthy young males and Panel C will consist of subjects with mild to moderate hypertension.</brief_summary>
	<brief_title>A Single Dose Study of MK8266 (8266-001)</brief_title>
	<detailed_description />
	<criteria>For Panel A and B Subject is a healthy male between 18 to 45 years of age. For Panel C subject is a male with essential hypertension between 18 to 55 years of age Subject is a nonsmoker Subject has a history of stroke, chronic seizure or major neurological disorder Subject has a disability that can interfere with rising from a sitting position to the standing position Subject has a personal of family history of bleeding or clotting disorders Subject has a history of cancer Subject is unable to refrain from or anticipates the use of any prescription or nonprescription drug during the study Subject consumes excessive amounts of caffeine or alcohol Subject has had major surgery, donated blood or participated in another investigational study in the past 4 weeks</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>